Evidence map›Paper›PMID 39616180›Full record

ArticleNature communications2024

Photochemically-enabled, post-translational production of C-terminal amides.

David Hymel, Felix Wojcik, Kim S Halskov, Wouter F J Hogendorf, Sydnee C Wong, Ben M Williams, Asmus R Mortensen, Nick Cox, Ayesha Misquith, Nanna B Holländer and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Molecular Design of Unimolecular Tetra-Receptor Agonists.Journal of the American Chemical Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

David Hymel *Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Felix Wojcik *Research Chemistry, Novo Nordisk A/S, Måløv, Denmark.ORCID 0000-0003-3444-6468
Kim S HalskovResearch Chemistry, Novo Nordisk A/S, Måløv, Denmark.
Wouter F J HogendorfResearch Chemistry, Novo Nordisk A/S, Måløv, Denmark.ORCID 0000-0003-3231-5325
Sydnee C WongNovo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Ben M WilliamsChemical Development, Novo Nordisk A/S, Bagsværd, Denmark.
Asmus R MortensenChemical Development, Novo Nordisk A/S, Bagsværd, Denmark.
Nick CoxNovo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Ayesha MisquithNovo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Nanna B HolländerChemical Development, Novo Nordisk A/S, Bagsværd, Denmark.
Finn MatthiesenPurification Technologies, Novo Nordisk A/S, Måløv, Denmark.
Suneet MehrotraNovo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Michael R HarrisNovo Nordisk Research Center Seattle, Inc., Seattle, WA, USA. vmlh@novonordisk.com.ORCID 0000-0001-8653-0843

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C-terminal α-amidated peptides are attractive therapeutic targets, but preparative methods to access amidated pharmaceuticals are limited both on lab and manufacturing-scale. Here we report a straightforward and scalable approach to the C-terminal α-amidation of peptides and proteins from cysteine-extended polypeptide precursors. This amidation protocol consists of three highly efficient steps: 1) selective cysteine thiol substitution with a photolabel, 2) photoinduced decarboxylative elimination and 3) enamide cleavage by simple acidolysis or inverse electron demand Diels-Alder reaction. We provide a blueprint for applying this protocol to the semi-recombinant production of therapeutically relevant targets where gram scale C-terminal α-amidation is achieved in a photoflow reactor on a recombinantly prepared peptide YY analogue and a GLP-1/amylin co-agonist precursor peptide. Robust performance of this reaction cascade in flow highlights the potential of this chemistry to enable amidated drug leads to enter development that would not be viable on commercial scale using existing technology.

Indexed as

AmidesProtein Processing, Post-TranslationalCycloaddition ReactionCysteineGlucagon-Like Peptide 1HumansPeptidesPhotochemical ProcessesAmidesCysteineGlucagon-Like Peptide 1Peptides

Identifiers

PMID39616180
PMCPMC11608224

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.